Acceleron

Pharma

Merck's Winrevair cuts death, morbidity risk by 76%

Merck revealed data from a phase 3 study of Winrevair, which showed it reduced the risk of all-cause death, lung transplant or hospitalization by 76%.

Kevin Dunleavy Mar 31, 2025 10:00am

After trial success, Merck halts a different Winrevair study

Jan 30, 2025 6:45am

Survey indicates Merck's Winrevair is set for 'strong uptake'

Jan 24, 2025 11:52am

Merck preps filings after Winrevair succeeds in severe PAH study

Nov 25, 2024 9:00am

Merck touts newly approved Winrevair as example of BD acumen

Apr 25, 2024 11:06am

FDA signs off on Merck’s potential blockbuster Winrevair for PAH

Mar 26, 2024 5:11pm